Trial results from DESTINY-Breast06 indicate the effectiveness of fam-trastuzumab deruxtecan-nxki in delaying disease progression for patients with hormone receptor (HR)–positive and HER2-low ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback